A number of significant industry participants place a high priority on the development of biosimilars. By December 2022, 25 biosimilars had been introduced in the US and 40 had received FDA approval. FDA approvals fell off dramatically during the COVID-19 pandemic, but they resumed in 2022 with the approval of seven new biosimilars. No biosimilars were approved in 2022 citing new reference items; the seven biosimilars that were approved in 2022 all referenced products that had previously received approval as biosimilars. In addition, four additional products were introduced in 2022, including the first two biosimilar versions of Lucentis (ranibizumab). Furthermore, the FDA approved Rezvoglar (referring to Lantus (insulin glargine)) and Cimerli (referring to Lucentis (ranibizumab)) as two novel interchangeable biosimilars in 2022. The number of development programs taking part in the FDA's Biosimilar Development Program has increased even if there was a general decrease in approvals between 2020 and 2021. There were about 60-70 biosimilars undergoing pipeline research as of April 2023. (Clinical.gov); in three to four years, half of them will be introduced. Growing biosimilar approvals will provide access to a larger range of treatments and propel market expansion.
Because developing nations sometimes have laxer regulations, biosimilar firms can find substantial development prospects in the Asia Pacific, Latin America (LATAM), and Middle East markets. Their legislative processes, payer views, pricing, affordability, and competitive landscapes are different from those of established markets. Because of their cheap labor and laboratory setup costs as well as their abundance of qualified personnel, China and India are viewed as desirable locations for global biosimilar development and manufacturing companies to outsource their research and development (R&D). Important market participants have shown a great deal of interest in this.
Asia Pacific's market is a vibrant and quickly changing sector, driven by a few major firms like Dr. Reddy's Laboratories (India), Celltrion (South Korea), Samsung Bioepis (South Korea), Biocon, and Shanghai Henlius Biotech (China). These businesses have been crucial to the development and implementation of biosimilars in the area, and it is anticipated that they will continue to spur innovation and expansion in the years to come.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Biosimilars Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Biosimilars Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Biosimilars Market based on Product
• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins
Biosimilars Market based on Application
• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Rheumatoid Arthritis
• Chronic and Autoimmune Disorders
• Others
Biosimilars Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The market is divided into two segments based on the product: glycosylated and recombinant non-glycosylated proteins. The highest revenue share of 54.9% was generated by the recombinant non-glycosylated proteins category in 2022. This can be attributed to the growing number of regulatory approvals for biosimilars by different governments. For example, the U.S. Food and Drug Administration has already approved biosimilars for the reference product Humira (adalimumab), which is a significant medication that helps treat rheumatoid arthritis (RA), under the names Yuflyma (adalimumab-aaty) and Idacio (adalimumab-aacf), in May 2023 and December 2022, respectively. Furthermore, the growing incidence of long-term illnesses like diabetes may propel the market expansion in this particular sector.
The International Diabetes Federation's Atlas 2021 states that 537 million adults worldwide have diabetes, whereas the American Heart Association's data shows that the age-adjusted prevalence rate of cardiovascular disease was 7354.1 per 100,000 individuals in 2020. Over the course of the projection period, the recombinant glycosylated proteins segment is anticipated to rise at the quickest CAGR of 14.9%. Since the patents on biologics like erythropoietin (EPO), Humira, and Neulasta are about to expire, a number of companies are vying to enter the biosimilars market, which has the potential to dramatically accelerate market growth by providing patients with better access to medicines. Additionally, as a result of technological developments in the recombinant glycosylated proteins market, a number of therapeutics, including soluble receptors and modified proteins, have emerged. These developments have the potential to further propel the market's expansion.
The market has been divided into segments based on applications, including blood disorders caused by growth hormone deficiency, rheumatoid arthritis, cancer, and chronic and autoimmune disorders. Because autoimmune diseases are becoming more common and well-known, the chronic and autoimmune disorders category had the highest revenue share in 2022oroughly 21.6%. According to the National Institute of Environmental Health Sciences, autoimmune illnesses affect over 24 million people in the United States. Over the course of the forecast period, the oncology application category is anticipated to rise at the quickest CAGR of 17.0%.
Globally rising cancer cases are anticipated to be the main factor driving market expansion. As per the data disclosed by the World Cancer Research Fund International, over 18.1 million individuals were afflicted with cancer in 2020. The creation of biosimilars for cancer treatment can offer patients in low- and middle-income nationsowhere cancer patient mortality rates are higheroaffordable therapeutic alternatives. Improving the availability of reasonably priced care can help the market grow even more.
Due to the existence of significant companies and a robust regulatory environment for biosimilars, North America dominated the market in 2022 with the biggest revenue share of 40.4%. Furthermore, biosimilars are reasonably accessible in the area. The U.S. Generic Biosimilars Saving Report 2021 states that there have been 20 biosimilars introduced and 31 approved in the country, adding up to around 10 million therapy days. The price of the 20 biosimilars that were introduced in the United States is 30% less than that of the biologics, which has led to a decrease in the cost of both biosimilars and biologics. It is anticipated that this cost reduction will give biosimilars in this area even more momentum.
Over the course of the projection period, Asia Pacific is anticipated to develop at the fastest CAGR of 18.4%. Important companies including Pfizer Inc., Celltrion, Biocon, and Dr. Reddy's Laboratories have made it easier for biosimilars to be developed and sold in this area. For example, Dr. Reddy's Laboratories introduced a biosimilar of Roche's Avastin in India in August 2019, making it easier to treat a variety of tumors. Biosimilars are predicted to rise rapidly in this region due to similar market developments and rising health care costs. The World Bank data, which was collected in April 2023, indicates that China's health expenditures as a percentage of GDP climbed from 4.98% in 2015 to 5.59% in 2020.
• This report illustrates the most vital attributes of the Biosimilars Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Biosimilars Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Biosimilars Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Biosimilars Market.
Table of Contents 1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Product: Market Size & Analysis 5.1. Overview 5.2. Recombinant Non-glycosylated Proteins 5.3. Recombinant Glycosylated Proteins 5.4. Others 6. Application: Market Size & Analysis 6.1. Overview 6.2. Oncology 6.3. Blood Disorders 6.4. Growth Hormonal Deficiency 6.5. Rheumatoid Arthritis 6.6. Chronic and Autoimmune Disorders 6.7. Others 7. Geography: Market Size & Analysis 7.1. Overview 7.2. North America (U.S., Mexico, Canada) 7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 7.5. Latin America (Brazil, Argentina) 7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 8. Competitive Landscape 8.1. Competitor Comparison Analysis 8.2. Market Developments 8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 8.2.2. Product Launches and execution 9. Vendor Profiles 9.1. AMGEN INC. 9.1.1. Overview 9.1.2. Financial Overview 9.1.3. Product Offerings 9.1.4. Developments 9.1.5. Business Strategy 9.2. F HOFFMAN-LA ROCHE LTD. 9.2.1. Overview 9.2.2. Financial Overview 9.2.3. Product Offerings 9.2.4. Developments 9.2.5. Business Strategy 9.3. SANDOZ INTERNATIONAL GMBH 9.3.1. Overview 9.3.2. Financial Overview 9.3.3. Product Offerings 9.3.4. Developments 9.3.5. Business Strategy 9.4. DR. REDDY'S LABORATORIES LTD. 9.4.1. Overview 9.4.2. Financial Overview 9.4.3. Product Offerings 9.4.4. Developments 9.4.5. Business Strategy 9.5. PFIZER INC. 9.5.1. Overview 9.5.2. Financial Overview 9.5.3. Product Offerings 9.5.4. Developments 9.5.5. Business Strategy 9.6. SAMSUNG BIOPIS 9.6.1. Overview 9.6.2. Financial Overview 9.6.3. Product Offerings 9.6.4. Developments 9.6.5. Business Strategy 9.7. BIOCON 9.7.1. Overview 9.7.2. Financial Overview 9.7.3. Product Offerings 9.7.4. Developments 9.7.5. Business Strategy 9.8. VIATRIS INC. 9.8.1. Overview 9.8.2. Financial Overview 9.8.3. Product Offerings 9.8.4. Developments 9.8.5. Business Strategy 9.9. CELLTRION HEALTHCARE CO.,LTD. 9.9.1. Overview 9.9.2. Financial Overview 9.9.3. Product Offerings 9.9.4. Developments 9.9.5. Business Strategy 9.10. ABBVIE INC. 9.10.1. Overview 9.10.2. Financial Overview 9.10.3. Product Offerings 9.10.4. Developments 9.10.5. Business Strategy 10. Analyst Opinion 11. Annexure 11.1. Report Scope 11.2. Market Definitions 11.3. Research Methodology 11.3.1. Data Collation and In-house Estimation 11.3.2. Market Triangulation 11.3.3. Forecasting 11.4. Report Assumptions 11.5. Declarations 11.6. Stakeholders 11.7. PFIZER INC. 12. Abbreviations
Tables TABLE 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION) TABLE 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 59. AMGEN INC. : FINANCIALS TABLE 60. AMGEN INC. : PRODUCTS & SERVICES TABLE 61. AMGEN INC. : RECENT DEVELOPMENTS TABLE 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS TABLE 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES TABLE 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS TABLE 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS TABLE 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES TABLE 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS TABLE 68. DR. REDDY'S LABORATORIES LTD.: FINANCIALS TABLE 69. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES TABLE 70. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS TABLE 71. PFIZER INC.: FINANCIALS TABLE 72. PFIZER INC.: PRODUCTS & SERVICES TABLE 73. PFIZER INC.: RECENT DEVELOPMENTS TABLE 74. SAMSUNG BIOPIS: FINANCIALS TABLE 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES TABLE 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS TABLE 77. BIOCON: FINANCIALS TABLE 78. BIOCON: PRODUCTS & SERVICES TABLE 79. BIOCON: DEVELOPMENTS TABLE 80. VIATRIS INC.: FINANCIALS TABLE 81. VIATRIS INC.: PRODUCTS & SERVICES TABLE 82. VIATRIS INC.: RECENT DEVELOPMENTS TABLE 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS TABLE 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES TABLE 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS TABLE 86. ABBVIE INC.: FINANCIALS TABLE 87. ABBVIE INC.: PRODUCTS & SERVICES TABLE 88. ABBVIE INC.: RECENT DEVELOPMENTS Charts CHART. 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION) CHART. 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 59. AMGEN INC. : FINANCIALS CHART. 60. AMGEN INC. : PRODUCTS & SERVICES CHART. 61. AMGEN INC. : RECENT DEVELOPMENTS CHART. 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS CHART. 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES CHART. 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS CHART. 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS CHART. 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES CHART. 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS CHART. 68. DR. REDDY'S LABORATORIES LTD.: FINANCIALS CHART. 69. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES CHART. 70. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS CHART. 71. PFIZER INC.: FINANCIALS CHART. 72. PFIZER INC.: PRODUCTS & SERVICES CHART. 73. PFIZER INC.: RECENT DEVELOPMENTS CHART. 74. SAMSUNG BIOPIS: FINANCIALS CHART. 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES CHART. 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS CHART. 77. BIOCON: FINANCIALS CHART. 78. BIOCON: PRODUCTS & SERVICES CHART. 79. BIOCON: DEVELOPMENTS CHART. 80. VIATRIS INC.: FINANCIALS CHART. 81. VIATRIS INC.: PRODUCTS & SERVICES CHART. 82. VIATRIS INC.: RECENT DEVELOPMENTS CHART. 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS CHART. 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES CHART. 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS CHART. 86. ABBVIE INC.: FINANCIALS CHART. 87. ABBVIE INC.: PRODUCTS & SERVICES CHART. 88. ABBVIE INC.: RECENT DEVELOPMENTS
Publisher: IHR Insights
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support